| Literature DB >> 33304005 |
Antonio Cordeiro da Silva Filho1, Tamara Oliveira Rocha1, Jorge Elias1, Marcus Vinicius de Castro Barros1, Alfredo Ribeiro Silva1, Rodolfo Borges Dos Reis1, Valdair Francisco Muglia1.
Abstract
OBJECTIVE: To determine whether evaluating the mean apparent diffusion coefficient (ADC) together with capsular contact (CC) adds value in the prediction of microscopic extracapsular extension (ECE) of prostate cancer.Entities:
Keywords: Diffusion magnetic resonance imaging; Magnetic resonance imaging; Neoplasm staging; Prostatic neoplasms
Year: 2020 PMID: 33304005 PMCID: PMC7720667 DOI: 10.1590/0100-3984.2019.0123
Source DB: PubMed Journal: Radiol Bras ISSN: 0100-3984
Acquisition parameters for the MRI protocol.
| Plane and weighting | Sequence | TR/TE (ms) | Flip angle (°) | Slice thickness (mm) | Field of view (cm) | Matrix | Maximum b value |
|---|---|---|---|---|---|---|---|
| Axial T2 | TSE | 3060/100 | 90 | 3 | 150 × 150 | 232 × 184 | — |
| Coronal T2 | TSE | 2444/120 | 90 | 3 | 150 × 150 | 248 × 198 | — |
| Sagittal T2 | TSE | 3770/120 | 90 | 3 | 260 × 260 | 360 × 275 | — |
| Axial DWI | SE EPI | 1561/71 | 90 | 5 | 304 × 375 | 152 × 152 | 1000/1400 |
| Axial perfusion | THRIVE | 43.865 | 10 | 4 | 297 × 345 | 172 × 172 | — |
| Axial T1 | TSE | 443/15 | 90 | 3 | 180 × 180 | 180 × 143 | — |
TR/TE, repetition time/echo time; TSE, turbo spin-echo; SE, spin-echo; EPI, echo-planar imaging; THRIVE, T1-weighted high resolution isotropic volume examination.
Value of b expressed in s/mm2.
Figure 1A 63-year-old male patient with a serum PSA of 7.51 ng/dL. Prostate cancer with a Gleason score of 7 (4+3, 6 positive fragments out of 12) and a clinical stage of 2a. A: Axial T2-weighted image showing the absence of macroscopic ECE, the extent of capsular contact being determined to be 21.0 mm by observer 1 and 17.8 mm by observer 2 (blue line). B: ADC map showing the extent of capsular contact, which was determined to be 17.9 mm by observer 1 and 14.5 mm by observer 2 (blue line). C: Histological section; hematoxylin-eosin staining shows the tumor tissue (T), a preserved capsule (C), and periprostatic fat (F).
Demographic, clinical, and histopathological characteristics.
| Characteristic | No ECE (n = 44) | Microscopic ECE (n = 12) | Macroscopic ECE(n = 11) | |
|---|---|---|---|---|
| Age (years) | 63.8 ± 7.1 | 61.8 ± 9.5 | 64.4 ± 6.9 | 0.75 |
| Serum PSA (ng/dL) | 9.5 ± 5.86 | 9.83 ± 6.86 | 19.9 ± 11.98 | 0 |
| Lesion size (mm) | 13.3 ± 4.6 | 17.6 ± 6.4 | 22.4 ± 13.2 | 0 |
| Clinical stage | 0.0004 | |||
| T1 | 18 (40.9) | 1 (8.3) | 0 | |
| T2a | 11 (25.0) | 4 (33.3) | 0 | |
| T2b | 9 (20.4) | 4 (33.3) | 1 (9.1) | |
| T2c | 6 (13.7) | 1 (8.3) | 2 (18.2) | |
| T3a/b | 0 | 2 (16.7) | 8 (66.7) | |
| Gleason score (ISUP grade) | 0.0001 | |||
| 3+3 (1) | 13 (29.5) | 0 | 0 | |
| 3+4 (2) | 18 (40.9) | 5 (41.7) | 2 (18.1) | |
| 4+3 (3) | 9 (20.5) | 6 (50.0) | 3 (27.3) | |
| 4+4, 3+5, 5+3 (4) | 3 (6.8) | 0 | 3 (27.3) | |
| 4+5, 5+4, 5+5 (5) | 1 (2.3) | 1 (8.3) | 3 (27.3) | |
| Positive fragments on biopsy (%) | 37.7 ± 24.6 | 49.3 ± 21.2 | 57.5 ± 23.7 | 0.02 |
| PI-RADS classification | 0.0001 | |||
| 2 | 2 (4.6) | 0 | 0 | |
| 3 | 10 (22.7) | 0 | 0 | |
| 4 | 23 (52.3) | 5 (41.7) | 0 | |
| 5 | 9 (20.4) | 7 (58.3) | 11 (100) | |
| Mean ADC (10–3 mm2/s) | 1.241 ± 0.26 | 1.13 ± 0.34 | 0.96 ± 0.18 | 0.01 |
| CCT2 (mm) | 9.0 ± 8.1 (0–21) | 18.3 ± 9.0 (8–37) | 24.0 ± 14.4 (13–65) | 0.00001 |
| CCDWI (mm) | 10.2 ± 8.6 (0–24) | 22.7 ± 11.1 (7–41) | 25.0 ± 15.5 (11–65) | 0.00001 |
Mean of the values measured by both observers. The values measured by each observer can be found in the text.
Diagnostic accuracy of the qualitative assessment of microscopic ECE only and of all cases of ECE (microscopic + macroscopic)
| Finding | Sensitivity | Specificity | PPV | NPV | Accuracy |
|---|---|---|---|---|---|
| Microscopic ECE | |||||
| Observer 1 | 0.583 (0.276–0.848) | 0.794 (0.635–0.907) | 0.466 (0.286–0.656) | 0.861 (0.757–0.925) | 0.745 (0.603–0.856) |
| Observer 2 | 0.500 (0.218–0.789) | 0.886 (0.754–0.962) | 0.545 (0.306–0.765) | 0.867 (0.785–0.920) | 0.803 (0.675–0.897) |
| Microscopic + macroscopic ECE | |||||
| Observer 1 | 0.522 (0.306–0.732) | 0.818 (0.673–0.918) | 0.600 (0.417–0.758) | 0.766 (0.676–0.839) | 0.716 (0.593–0.820) |
| Observer 2 | 0.500 (0.736–0.930) | 0.889 (0.759–0.963) | 0.687(0.466–0.847) | 0.784 (0.703–0.848) | 0.761 (0.641–0.857) |
PPV, predictive positive value; NPV, negative predictive value.
Figure 2A 60-year-old male patient, serum PSA = 25.6 ng/dL. Prostate cancer with a Gleason score of 7 (4+3, 7 positive fragments out of 12) and a clinical stage of 2b. A: Axial T2-weighted image showing slight bulging of the capsule but no conclusive signs of macroscopic ECE, the extent of capsular contact being determined to be 22.1 mm by observer 1 and 23.1 mm by observer 2 (blue line). B: ADC map showing the extent of capsular contact, which was determined to be of 23.1 mm by observer 1 and 28.2 mm by observer 2 (blue line). C: Histological section; hematoxylin-eosin staining shows the tumor (T) extending beyond the capsule (C) with an intracapsular component (IC) and tumor tissue approaching the periprostatic fat (F).
Diagnostic accuracy based on the AUC for capsular contact as measured by both observers on T2-weighted images and DWI.*
| Finding | CCT2 | CCDWI | ADC | ADC+CCT2 | ADC+CCDWI |
|---|---|---|---|---|---|
| Microscopic ECE | |||||
| Observer 1 | 0.728 (0.567–0.889) | 0.691 (0.523–0.889) | 0.675 (0.480–0.871) | 0.714 (0.537–0.890) | 0.678 (0.505–0.804) |
| Observer 2 | 0.782 (0.644–0.919) | 0.821 (0.687–0.950) | 0.799 (0.640–0.954) | 0.869 (0.780–0.959) | 0.870 (0.778–0.961) |
| Microscopic + macroscopic ECE | |||||
| Observer 1 | 0.758 (0.642–0.875) | 0.743 (0.623–0.863) | 0.778 (0.651–0.906) | 0.757 (0.643–0.878) | 0.741 (0.615–0.864) |
| Observer 2 | 0.833 (0.736–0.930) | 0.832 (0.730–0.934) | 0.855 (0.757–0.954) | 0.871 (0.782–0.960) | 0.849 (0.752–0.945) |
Results shown as AUC (95% confidence interval).
Univariate and multivariate logistic regression analyses of the combination of clinical and imaging variables with ECE, for both observers.
| Variable | Observer 1 | Observer 2 | |||
|---|---|---|---|---|---|
| Univariate analysis Odds ratio ± SD (95% CI) | Multivariate analysis Odds ratio ± SD (95% CI) | Univariate analysis Odds ratio ± SD (95% CI) | Multivariate analysis Odds ratio ± SD (95% CI) | ||
| Serum PSA | 1.08 ± 0.04 (1,01–1.16) 0.02 | 0.93 ± 0.97 (0.09–1.91) 0.42 | 1.08 ± 0.04 (1.01–1.16) 0.02 | 1.06 ± 0.52 (0.97–1.17) 0.19 | |
| Gleason score (ISUP grade) | 2.59 ± 0.75 (1.46–4.58) 0.001 | 1.95 ± 1.08 (0.66–5.77) 0.22 | 2.59 ± 0.75 (1.46–4.58) 0.001 | 1.66 ± 0.68 (0.74–3.71) 0.22 | |
| Positive fragments on biopsy (%) | 1.02 ± 0.01 (1.00–1.05) 0.02 | 1.00 ± 0.02 (0.96–1.05) 0.71 | 1.02 ± 0.01 (1.00–1.05) 0.02 | 0.99 ± 0.02 (0.96–1.03) 0.68 | |
| Tumor size | 1.19 ± 0.07 (1.06–1.33) 0.002 | 1.26 ± 0.18 (0.94–1.68) 0.11 | 1.16 ± 0.07(1.02–1.31) 0.02 | 1.12 ± 0.15 (0.87–1.47) 0.38 | |
| PI-RADS | 3.65 ± 1.90 (1.31–10.10) 0.01 | 2.09 ± 1.62 (0.45–9.55) 0.34 | 4.80 ± 2.91 (1.47–15.60) 0.009 | 0.37 ± 0.48 (0.02–4.79) 0.44 | |
| CCT2 | 1.08 ± 0.03 (1.01–1.15) 0.02 | 1.07 ± 0.11 (0.87–1.32) 0.48 | 1.17 ± 0.05 (1.07–1.28) 0.0001 | 0.92 ± 0.10 (0.73–1.17) 0.53 | |
| CCDWI | 1.06 ± 0.32 (1.00–1.12) 0.04 | 0.92 ± 0.10 (0.74–1.14) 0.46 | 1.14 ± 0.04 (1.06–1.23) 0.0001 | 1.10 ± 0.11 (0.90–1.34) 0.35 | |
| Mean ADC | 6.58 ± 11.70 (0.20–214) 0.23 | 0.07 ± 0.81 (0.01–16.2) 0.34 | 783.2 ± 1890.5 (6.90–8879) 0.006 | 955.4 ± 3643.4 (0.54–1682) 0.07 | |
SD, standard deviation; 95% CI, 95% confidence interval.